The US Food and Drug Administration (FDA) has approved for OncoImmune to conduct a Phase III clinical trial of CD24Fc to treat patients hospitalised with Covid-19.
CD24Fc modulates host inflammatory response to tissue injuries, believed to be involved in autoimmune disease, cancer, graft-versus-host disease (GvHD) and metabolic syndromes.
The novel coronavirus, SARS-CoV-2, leads to clinical symptoms by killing the lung cells, causing inflammation that worsens those clinical symptoms.
OncoImmune co-founder and CEO Dr Yang Liu said: “CD24Fc is a first-in-class biologic that fortifies an innate immune checkpoint against excessive inflammation caused by tissue-injuries. “We are very excited to launch a global effort to test the clinical